It has a 4-iodophenyl butanoic group that interacts with serum albumin to elongate the circulation time of the compound and subsequently increase the uptake of the therapeutic radiopharmaceutical by prostate cancer cells. The gene discussed is ALB; the disease is prostate cancer.